Acrux ROA

Co dělá Acrux? Acrux Ltd is an Australian pharmaceutical company specializing in the development and marketing of products in the dermatology field. The company was founded in 1998 and is headquartered in Melbourne. Its history begins with the development of a groundbreaking technology called the "Sprayform® Technology," which allows the administration of liquid medications in spray form, providing numerous advantages compared to traditional administration methods. Acrux obtained the first patent for this technology in 1999 and worked on bringing it to the market. Its business model focuses on licensing its Sprayform® Technology to third parties to advance the development and marketing of products in various therapeutic areas. The company has an experienced research and development team that collaborates closely with partners to develop tailored solutions and support the entire development process, ensuring that all products meet the highest quality standards and regulatory requirements. Acrux Ltd is divided into various divisions, including products for women, diabetes, pain and inflammation, as well as neurology and psychiatry. With its Sprayform® Technology, the company has developed unique therapeutic solutions that meet patients' needs. For example, a testosterone preparation for women has been developed that is simply applied as a spray and offers higher efficacy than traditional tablets. Another product is a fast-acting pain reliever that is administered through a nasal spray. Acrux Ltd also has partnerships with major pharmaceutical companies such as Eli Lilly, Johnson & Johnson, Pfizer, and Sanofi. These partnerships enable Acrux to market its technology globally and offer its customers a comprehensive portfolio of tailored solutions. The partner is granted exclusive rights to use the technology for specific products and markets, facilitating the development of new products and the expansion into new regions. Overall, Acrux Ltd has achieved a leadership position in the field of transdermal systems and transmucosal technologies through its innovative Sprayform® Technology. The company aims to further expand its leadership position by focusing on the development of new products and collaboration with partners. Acrux remains in constant exchange with the scientific community to incorporate the latest research and development insights into its products. Acrux je jednou z nejoblíbenějších společností na Eulerpool.com.